Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Bevacizumab with FOLFOX for Resectable Colorectal Cancer Liver Metastases
NCT06280495Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of serplulimab and bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: 3-year Progression-Free Survival Rate. Started Feb 2024; status: recruiting.
02
Drugs
serplulimabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06280495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280495.